Abstract
Colorectal cancer (CRC) is the third most common form of cancer and the second leading cause of cancer-related deaths worldwide. In the United States, it is also ranked third in cancer incidence and also is the second leading cause of cancer-related mortality. It is estimated that there will be 102,480 and 40,340 new cases of colon and rectal cancer in the United States in 2013 with approximately 50,830 deaths from CRC combined. Current treatments for CRC consists of surgical resection most often combined with chemotherapy and/or radiation for more advanced stages. However, a significant number of patients experience recurrent disease with less successful treatment options. Therefore, new strategies for the treatment of CRC are needed. In addition, several promising molecular targets have been identified for prevention of CRC and offer hope that clinically efficacious chemopreventive agents will be available in the future, especially for high-risk populations. In this Special Issue of Molecular Carcinogenesis, we highlight a number of articles that deal with understanding mechanisms associated with CRC development and progression. The goal of these studies is to identify molecular targets for prevention and/or treatment of CRC.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
